CLDX - Celldex Therapeutics, Inc. - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

2.115B

Cash

823.8M

Avg Qtr Burn

-29.84M

Short % of Float

11.24%

Insider Ownership

0.29%

Institutional Own.

Qtr Updated

03/31/24

Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Barzolvolimab (CDX-0159) (KIT receptor) Details Prurigo nodularis, Skin disease/disorder	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Barzolvolimab (CDX-0159) Details Eosinophilic Gastritis, Eosinophilic Esophagitis	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Barzolvolimab (CDX-0159) (KIT receptor) Details Chronic inducible urticaria	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Barzolvolimab (CDX-0159) (KIT receptor) Details KIT/Mast cell diseases, Chronic spontaneous urticaria, Chronic urticaria	Phase 2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Barzolvolimab (CDX-0159) (KIT receptor) Details Skin disease/disorder, Atopic dermatitis	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CDX-585 Details Solid tumor/s, Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CDX-527 (and PD-L1 / CD27) Details Solid tumor/s, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CDX-1140 (CD40 agonist) Details Solid tumor/s, Cancer, Diffuse large B cell lymphoma	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.